Why Is McKesson Stock Trading Lower Today? - McKesson (NYSE:MCK)

McKesson beats expectations with Q3 2024 sales of $80.9 billion, up 15%. U.S. Pharmaceutical Segment thrives, adjusted EPS at $7.74, exceeding consensus.

Related Keywords

Allison Jacobsen ,Mckesson Corporation ,Eric Coldwell ,Citigroup ,Prescription Technology Solutions ,Mckesson ,Prescription Technology Solutions Segment ,Rite Aid ,Prescription Technology Solutions Rx ,Technology Solutions Segment ,Bankrupt Rite Aid ,Prescription Technology ,Technology Solutions ,